Overview

Developing Technologies For Tomorrow’s Therapies

 

Caladrius leverages the manufacturing expertise of its subsidiary, PCT, a leading development and manufacturing partner to the cell therapy industry. PCT develops selected potentially disruptive cell therapies through preclinical or early-stageclinical studies  to their next clinical milestone (likely proof-of-concept), a main inflection point in the life of a product. Thesetherapies are identified based on the Company’s constant exposure to new developments in the industry through PCT. Caladrius then intends to seek partners or out-license the technologiesfor execution of the remainder of the development and regulatory process. In so doing, Caladrius hopes to promote revenue growth at PCT as the preferred cGMP manufacturing partner for cell therapy developers whose product are ready for later-stage clinical studies and commercialization.

Early Onset of Diabetes: CLBS03

Caladrius is currently focused on developing an autologous T-regulatory (Treg) cell-based therapy (CLBS03) for the treatment of recent-onset  type 1 diabetes mellitus (T1DM).  Learn more.